ADHERA THERAPEUTICS INC - ATRX STOCK NEWS

Adhera Therapeutics (OTCQB: ATRX) has appointed Dr. Zahed Subhan as its new CEO, effective September 30, 2022, marking a strategic shift towards a clinical stage biopharmaceutical company. Dr. Subhan, who has over 35 years of experience in the pharmaceutical industry, aims to enhance shareholder value and expedite the development of treatments for Parkinson's disease and Type 1 diabetes. Current CEO Andrew Kucharchuk will transition to the role of COO. The company is also set to unveil a new corporate website to better represent its portfolio.

Adhera Therapeutics (OTCQB: ATRX) announced a Heads of Terms agreement with Bio Innovation Group to acquire Paclitaxel Gallium Transferrin (PGT), a targeted treatment for advanced cancers. PGT delivers paclitaxel specifically to cancer cells that over-express the Transferrin Receptor 1 (CD71), potentially improving therapeutic efficacy compared to existing options. The acquisition aims to leverage PGT's unique delivery mechanism to enhance cancer treatment. While no guarantees exist for a finalized agreement, the company sees PGT as a valuable addition to its pipeline for developing innovative cancer therapies.

Adhera Therapeutics (OTCQB: ATRX) appointed Trond K. Waerness as Chairman of the Board as of May 19, 2022. With 25 years of pharmaceutical experience, Waerness replaces Andrew Kucharchuk, who remains CEO. Adhera is focused on advancing its drug candidates, MLR-1023 for Type 1 diabetes and MLR-1019 for Parkinson’s disease, into Phase 2 clinical trials. Both compounds have shown promising safety profiles. The company aims for NASDAQ uplisting, enhancing shareholder value through clinical development.

Adhera Therapeutics (OTCPK: ATRX) has appointed Dr. Jean Buteau to its Scientific Advisory Board to enhance its diabetes drug development efforts. Dr. Buteau, a renowned expert in diabetes, will support the advancement of MLR-1023, a Phase 2-ready candidate aimed at treating Type 1 diabetes. MLR-1023 has shown impressive safety and tolerability in over 700 patients during prior trials. This collaboration signifies a strategic move to potentially impact the treatment landscape for the 9 million individuals affected by diabetes globally.

Adhera Therapeutics, Inc. (OTCPK: ATRX) announced its successful uplisting from OTC Pink Sheets to OTCQB Venture Marketplace effective January 20, 2022. This move aims to enhance visibility for retail and institutional investors and improve trading liquidity. The OTCQB, recognized by the SEC, supports developing companies meeting ongoing requirements. CEO Andrew Kucharchuk emphasized the uplisting as a commitment to compliance and quality, marking a significant milestone for Adhera as it seeks to advance its drug pipeline into Phase 2 clinical trials.

Adhera Therapeutics (OTCPK: ATRX) announced the issuance of a new Canadian patent for MLR-1019 (armesocarb), aimed at treating dyskinesia and related disorders. This expands its patent estate to 13 issued patents and 6 pending patents worldwide. Adhera plans to develop MLR-1019 as a unique therapy for Parkinson’s disease, addressing both movement and non-movement symptoms. The company will initiate a Phase 2a clinical trial in Eastern Europe and conduct IND-enabling studies in the U.S., leveraging extensive clinical data from similar compounds.

Adhera Therapeutics (OTCPK: ATRX) has appointed Dr. Zahed Subhan to its Board of Directors. With over 30 years in the pharmaceutical and biotechnology sectors, Dr. Subhan's expertise spans drug development in neurology, psychiatry, oncology, and more. He has held significant roles such as CEO of NuEvolution A/S and Chief Business Officer at Gemini Genomics Inc. His leadership is expected to enhance Adhera's pipeline, particularly for MLR-1023, a candidate for Type 1 diabetes, as the company prepares for a Phase 2b trial.

Adhera Therapeutics (OTCPK: ATRX) has expanded its licensing agreement with Melior Pharmaceuticals to advance MLR-1023 (tolimidone) into Phase 2 trials targeting Type 1 diabetes, along with new indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation. MLR-1023 has shown strong safety and tolerability in prior studies involving over 700 patients. The NASH market is expected to reach $21.48 billion by 2025, driven by increasing incidence rates. Adhera is exploring abbreviated developmental pathways for these indications based on existing clinical data.

Adhera Therapeutics, Inc. (OTCPK: ATRX) has commenced manufacturing MLR-1019 (armesocarb) for a Phase 2a clinical trial targeting Parkinson's disease (PD), aiming to address both movement and non-movement symptoms. The trial will be a multi-center, double-blind study in Eastern Europe, focusing on patients with L-DOPA induced dyskinesia. Additionally, Adhera has secured a new patent for MLR-1019 in Korea, expanding its patent portfolio to 12 issued patents globally. The company is optimistic about the accelerated development pathway for MLR-1019 due to extensive historical data from mesocarb.